AAV-Mediated Oligodendrocyte Reprogramming Without Retroviral Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for transdifferentiating oligodendrocytes and oligodendrocyte precursor cells into neurons are limited by the use of transgenic mice or retroviral vectors, which pose risks of insertional mutagenesis and are not suitable for clinical applications.
Innovation Solution
Development of a novel AAV vector with a chimeric capsid that confers dominant oligodendrocyte tropism, combined with an expression cassette targeting polypyrimidine tract binding protein 1 (PTBP1) to attenuate its expression, facilitating the transdifferentiation of oligodendrocytes and oligodendrocyte precursor cells into functional neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If retroviral vectors are used for transdifferentiation, then neuronal reprogramming can be achieved, but insertional mutagenesis risk increases making it unsuitable for clinical applications
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as an intermediary delivery system instead of retroviral vectors. AAV vectors achieve the same transdifferentiation effect (converting oligodendrocytes to neurons) without the insertional mutagenesis risk, as they do not integrate into the host genome. This intermediary approach maintains therapeutic efficacy while eliminating the harmful side effect.
Solution Approach 2:
The patent employs transient expression of transdifferentiation factors (such as NeuroD1, Brn2, and Myt1l) delivered via AAV vectors that do not permanently integrate. This disposable approach allows the therapeutic effect to be achieved without long-term genomic alteration, reducing safety risks while maintaining the ability to reprogram cells into neurons.
2Reliability
If transgenic mice are used for transdifferentiation, then neuronal conversion can be achieved, but device complexity and clinical applicability decrease
Solution Approach 1:
The patent extracts the essential transdifferentiation factors (NeuroD1, Brn2, Myt1l) from the complex transgenic mouse model and delivers them separately via AAV vectors. This extraction simplifies the approach by removing the need for generating and maintaining transgenic animals, while preserving the core transdifferentiation mechanism for clinical application.
Solution Approach 2:
The patent segments the transdifferentiation process by delivering individual transcription factors (NeuroD1, Brn2, Myt1l) through separate AAV vectors rather than requiring a single complex transgenic model. This segmentation simplifies the system, allows for better control of each factor's expression, and facilitates translation to clinical settings where complex transgenic models are not feasible.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively transdifferentiates oligodendrocytes into functional neurons, increasing neuronal population in the brain, and offers a safer, clinically viable approach for treating central nervous system disorders.
Implementation Method 1
we recently developed a novel AAV vector where the chimeric capsid confers a dominant oligodendrocyte tropism in the rat striatum
Implementation Method 2
Xue et al. (Cell 152:82 (2013)) reported that suppression of polypyrimidine-tract-binding (PTB) protein expression in cultured fibroblasts caused a portion of the fibroblasts to differentiate into functional neurons
Data Source
AI summary
The invention relates to products and methods for transdifferentiating oligodendrocytes and/or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.